Загрузка...
Recent advances in theranostics and challenges for the future
Theranostic nuclear oncology is on the cusp of adoption into routine clinical management of neuroendocrine tumours (NETs) following publication of the Phase 3 randomised controlled trial, NETTER-1. For the first time, level 1b evidence of efficacy and safety of 68-gallium/177-lutetium-DOTA-octreotat...
Сохранить в:
| Опубликовано в: : | Br J Radiol |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
The British Institute of Radiology.
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6475948/ https://ncbi.nlm.nih.gov/pubmed/29565650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1259/bjr.20170893 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|